Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Jun;182(6):1495-1497.
doi: 10.1111/bjd.18855. Epub 2020 Jan 29.

Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab

W Shehadeh  1 , O Sarig  1 , J Bar  1 , E Sprecher  1   2 , L Samuelov  1
Affiliations
Case Reports

Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab

W Shehadeh et al. Br J Dermatol. 2020 Jun.
No abstract available

PubMed Disclaimer

References

    1. Mellerio JE, Ashton GH, Mohammedi R et al. Allelic heterogeneity of dominant and recessive COL7A1 mutations underlying epidermolysis bullosa pruriginosa. J Invest Dermatol 1999; 112:984-7.
    1. Deleuran M, Thaçi D, Beck LA et al. Dupilumab shows long-term safety and efficacy in patients with moderate-to-severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol 2019; in press.
    1. Napolitano M, Fabbrocini G, Scalvenzi M et al. Effectiveness of dupilumab for the treatment of generalized prurigo nodularis clinical phenotype of adult atopic dermatitis. Dermatitis 2020; 31:81-4.
    1. Pallesen KAU, Lindahl KH, Bygum A. Dominant dystrophic epidermolysis bullosa pruriginosa responding to naltrexone treatment. Acta Derm Venereol 2019; 99:1195-6.
    1. Takahashi T, Mizutani Y, Ito M et al. Dystrophic epidermolysis bullosa pruriginosa successfully treated with immunosuppressants. J Dermatol 2016; 43:1391-2.

Supplementary concepts